By modulating key molecular markers like VDR, VEGF, TGF-β1, and Nrf2 these treatments provide potential benefits in slowing DN progression and improving renal function, whether used to prevent or treat established DN. The gene discussed is NFE2L2; the disease is liver dysplastic nodule.